-1753895830833.webp&w=3840&q=75)
2025 NOSCM | CLL: Therapeutic Advances in 2025
Overview
Dr. Javier Pinilla-Ibarz highlighted 2025 CLL treatment shifts toward fixed-duration regimens. BTK+BCL-2 combos like Ibrutinib+Venetoclax showed 66% PFS in CAPTIVATE. MRD-guided Flare and triple-combo GAIA CLF 13 trials outperformed others, with SEQUOIA showing strong responses to Zanubrutinib+Venetoclax.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Javier Pinilla-Ibarz, MD, PhD
Date of Release
July 30th, 2025
-1753896080231.webp&w=3840&q=75)
-1753896006195.webp&w=3840&q=75)